Efficacy and Safety of the Biosimilar Recombinant Human Parathyroid Hormone Cinnopar(®) in Postmenopausal Osteoporotic Women: A Randomized Double-blind Clinical Trial

BACKGROUND: Due to high cost and burden of osteoporosis, it is reasonable to focus on the reduction of fractures as the main goal of treatment. We compared the efficacy and safety of a new biosimilar recombinant human parathyroid hormone (CinnoPar®, CinnaGen, Iran) to the reference product (Forteo®,...

Descripción completa

Detalles Bibliográficos
Autores principales: TABATABAEI-MALAZY, Ozra, NORANI, Masumeh, HESHMAT, Ramin, QORBANI, Mostafa, VOSOOGH, Afsaneh, AFRASHTEH, Behnaz, KAHKESHAN, Farzin, AJAMI, Arman, LARIJANI, Bagher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tehran University of Medical Sciences 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174042/
https://www.ncbi.nlm.nih.gov/pubmed/30320008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174042/
https://www.ncbi.nlm.nih.gov/pubmed/30320008

Ejemplares similares